A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder
William B. White(University of Connecticut), Michael C. Snabes(AbbVie (United States)), Scott Berry(Queen's University), Joanne Zborowski, Linda C. Giudice(Baylor College of Medicine), Deborah Grady(San Francisco VA Medical Center)
Cited by 67
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
|Hypertension|2018|1.1k
Clinical Practice Guidelines for the Management of Hypertension in the Community
|Journal of Clinical Hypertension|2013|1k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980